Discovery phase

Molecules in the discovery phase are developed using the research platform ISP. The goal is to identify molecules that are able to advance into preclinical development.


The P003 project aims to discover and develop dopamine D1 and D2 receptor agonist compounds with once-daily oral administration and improved efficacy on Parkinson’s core motor symptoms (tremor, rigidity, and slowness of movements) but are free from the limitations displayed by levodopa (i.e., the short duration of action and dyskinesia). Identified using IRLAB’s research platform ISP as well as specialized models of Parkinson’s, are a number of compounds that are orally available, potent, and display a long duration of efficacy, without inducing dyskinesia during long-term treatment. These compounds are clearly differentiated from today’s available levodopa treatments.

IRL1117 is the first drug candidate nominated for further development toward clinical studies from the P003 project. IRL1117 is an orally available and potent dopamine D1 and D2 receptor agonist that has demonstrated rapid onset and more than 10 hours of sustained efficacy in preclinical studies. In addition to IRL1117, there are a number of follow-on compounds identified with differentiation relating to the onset of action and time to maximal efficacy.